New Medium-Term Management Plan Targets for the Fiscal Year Ending March 2022 (Net Sales: ¥38.7 Billion; Overseas Net Sales: ¥9.46 Billion; Operating Profit: ¥5.32 Billion; Operating Margin: 13.7%; ROE: 10%)
First written in FY2019. 1 of 4 entries say "Softened", first in FY2020. Latest entry: FY2022.
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
- FY2022Overall target achieved; overseas net sales target not achievedAnnual report
「Net sales for the consolidated fiscal year increased to ¥42,996 million, up 11.2% year on year, as immunoserology reagents, including fecal occult blood testing reagents, grew substantially following the resumption of various health examinations and screening programs and the recovery trend in outpatient numbers, while sales of COVID-19 detection reagents also grew substantially in the fourth quarter amid the spread of COVID-19 infections.」
For the fiscal year ending March 2022, the targets for net sales, operating income, and ROE were achieved. Overseas sales, however, were ¥8,868 million, below the previous forecast of ¥9,090 million. - FY2021Upward revision to overall targets and reduction in overseas sales targetAnnual report
「For the fiscal year ending March 2022, we have raised our initial forecast and expect net sales of ¥40,400 million (including overseas sales of ¥9,090 million), operating income of ¥6,370 million (operating margin of 15.8%), and ROE of 11.5%.」
For the fiscal year ending March 2022, raised the targets for net sales, operating income, operating margin, and ROE, while reducing overseas sales from ¥9,460 million to ¥9,090 million. - FY2020SoftenedAnnual report
「We had established operating margin and ROE as target management indicators, and the overseas sales ratio as an indicator of globalization. However, as market uncertainty has increased due to the COVID-19 pandemic, it is currently difficult to calculate these indicators reasonably. Accordingly, forecasts from the fiscal year ending March 2021 onward are undetermined.」
Operating margin, ROE, and overseas sales ratio had been established as indicators, but forecasts from the fiscal year ending March 2021 onward were left undetermined due to uncertainty caused by the COVID-19 pandemic. - FY2019First statedAnnual report
「The Group aims to achieve, under its new medium-term management plan, net sales of ¥38,700 million (including overseas sales of ¥9,460 million), operating income of ¥5,320 million (operating margin of 13.7%), and ROE of 10% in the fiscal year ending March 2022.」
Set new numerical targets for the fiscal year ending March 2022: net sales, overseas sales, operating income, operating margin, and ROE.